Drug-Induced Peripheral Neuropathy: Diagnosis and Management

Diala      Merheb; Georgette      Dib; Maroun   Bou   Zerdan; Clara   El   Nakib; Saada      Alame; Hazem   I.   Assi
doi:10.2174/1568009621666210720142542
Abstract

Peripheral neuropathy comes in all shapes and forms and is a disorder which is found in the peripheral nervous system. It can have an acute or chronic onset depending on the multitude of pathophysiologic mechanisms involving different parts of nerve fibers. A systematic approach is highly beneficial when it comes to cost-effective diagnosis. More than 30 causes of peripheral neuropathy exist ranging from systemic and auto-immune diseases, vitamin deficiencies, viral infections, diabetes, etc. One of the major causes of peripheral neuropathy is drug-induced disease, which can be split into peripheral neuropathy caused by chemotherapy or by other medications. This review deals with the latest causes of drug-induced peripheral neuropathy, the population involved, the findings on physical examination and various workups needed and how to manage each case.
Keywords: Peripheral neuropathy, chemotherapy-induced, taxanes, platinum drugs, vinca alkaloids, proteasome inhibitors, epithelones, eribulin, brentuximab, suramin, nitrous oxide, disulfiram.
« Previous Next »
[1] 
Remiche, G.; Kadhim, H.; Maris, C.; Mavroudakis, N. Peripheral neuropathies, from diagnosis to treatment, review of the literature and lessons from the local experience. Rev. Med. Brux.,  2013, 34(4), 211-220.
[PMID: 24195230] 
[2] 
Singh, S.; Dallenga, T.; Winkler, A.; Roemer, S.; Maruschak, B.; Siebert, H.; Brück, W.; Stadelmann, C. Relationship of acute axonal damage, Wallerian degeneration, and clinical disability in multiple sclerosis. J. Neuroinflammation,  2017, 14(1), 57.
[http://dx.doi.org/10.1186/s12974-017-0831-8] [PMID: 28302146] 
[3] 
Hanewinckel, R.; Ikram, M.; Van Doorn, P. Peripheral neuropathies.Handbook of Clinical Neurology; Elsevier, 2016, 138, pp. 263-282.
[4] 
Hughes, R.A. Epidemiology of peripheral neuropathy. Curr. Opin. Neurol.,  1995, 8(5), 335-338.
[http://dx.doi.org/10.1097/00019052-199510000-00001] [PMID: 8542035] 
[5] 
Seretny, M.; Currie, G.L.; Sena, E.S.; Ramnarine, S.; Grant, R.; MacLeod, M.R.; Colvin, L.A.; Fallon, M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain,  2014, 155(12), 2461-2470.
[http://dx.doi.org/10.1016/j.pain.2014.09.020] [PMID: 25261162] 
[6] 
Gordon-Williams, R.; Farquhar-Smith, P. Recent advances in understanding chemotherapy-induced peripheral neuropathy. F1000 Res.,  2020, 9, 9.
[http://dx.doi.org/10.12688/f1000research.21625.1] [PMID: 32201575] 
[7] 
Weimer, L.H. Medication-induced peripheral neuropathy. Curr. Neurol. Neurosci. Rep.,  2003, 3(1), 86-92.
[http://dx.doi.org/10.1007/s11910-003-0043-8] [PMID: 12507417] 
[8] 
Morris, P.G.; Fornier, M.N. Microtubule active agents: beyond the taxane frontier. Clin. Cancer Res.,  2008, 14(22), 7167-7172.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-0169] [PMID: 19010832] 
[9] 
Yared, J.A.; Tkaczuk, K.H. Update on taxane development: new analogs and new formulations. Drug Des. Devel. Ther.,  2012, 6, 371-384.
[PMID: 23251087] 
[10] 
Hilkens, P.H.; Verweij, J.; Vecht, C.J.; Stoter, G.; van den Bent, M.J. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann. Oncol.,  1997, 8(2), 187-190.
[http://dx.doi.org/10.1023/A:1008245400251] [PMID: 9093729] 
[11] 
Chon, H.J.; Rha, S.Y.; Im, C.K.; Kim, C.; Hong, M.H.; Kim, H.R.; An, J.R.; Noh, S.H.; Chung, H.C.; Jeung, H.C. Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. Cancer Res. Treat.,  2009, 41(4), 196-204.
[http://dx.doi.org/10.4143/crt.2009.41.4.196] [PMID: 20057964] 
[12] 
Forsyth, P.A.; Balmaceda, C.; Peterson, K.; Seidman, A.D.; Brasher, P.; DeAngelis, L.M. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J. Neurooncol.,  1997, 35(1), 47-53.
[http://dx.doi.org/10.1023/A:1005805907311] [PMID: 9266440] 
[13] 
Winer, E.P.; Berry, D.A.; Woolf, S.; Duggan, D.; Kornblith, A.; Harris, L.N.; Michaelson, R.A.; Kirshner, J.A.; Fleming, G.F.; Perry, M.C.; Graham, M.L.; Sharp, S.A.; Keresztes, R.; Henderson, I.C.; Hudis, C.; Muss, H.; Norton, L. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J. Clin. Oncol.,  2004, 22(11), 2061-2068.
[http://dx.doi.org/10.1200/JCO.2004.08.048] [PMID: 15169793] 
[14] 
Park, S.B.; Goldstein, D.; Krishnan, A.V.; Lin, C.S.Y.; Friedlander, M.L.; Cassidy, J.; Koltzenburg, M.; Kiernan, M.C. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J. Clin.,  2013, 63(6), 419-437.
[http://dx.doi.org/10.3322/caac.21204] [PMID: 24590861] 
[15] 
Pace, A.; Nisticò, C.; Cuppone, F.; Bria, E.; Galiè, E.; Graziano, G.; Natoli, G.; Sperduti, I.; Jandolo, B.; Calabretta, F.; Tomao, S.; Terzoli, E. Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue? Clin. Breast Cancer,  2007, 7(7), 550-554.
[http://dx.doi.org/10.3816/CBC.2007.n.010] [PMID: 17509163] 
[16] 
Baldwin, R.M.; Owzar, K.; Zembutsu, H.; Chhibber, A.; Kubo, M.; Jiang, C.; Watson, D.; Eclov, R.J.; Mefford, J.; McLeod, H.L.; Friedman, P.N.; Hudis, C.A.; Winer, E.P.; Jorgenson, E.M.; Witte, J.S.; Shulman, L.N.; Nakamura, Y.; Ratain, M.J.; Kroetz, D.L. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin. Cancer Res.,  2012, 18(18), 5099-5109.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-1590] [PMID: 22843789] 
[17] 
Ghoreishi, Z.; Esfahani, A.; Djazayeri, A.; Djalali, M.; Golestan, B.; Ayromlou, H.; Hashemzade, S.; Asghari Jafarabadi, M.; Montazeri, V.; Keshavarz, S.A.; Darabi, M. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer,  2012, 12(1), 355.
[http://dx.doi.org/10.1186/1471-2407-12-355] [PMID: 22894640] 
[18] 
Chaudhry, V.; Chaudhry, M.; Crawford, T.O.; Simmons-O’Brien, E.; Griffin, J.W. Toxic neuropathy in patients with pre-existing neuropathy. Neurology,  2003, 60(2), 337-340.
[http://dx.doi.org/10.1212/01.WNL.0000043691.53710.53] [PMID: 12552058] 
[19] 
De Iuliis, F.; Taglieri, L.; Salerno, G.; Lanza, R.; Scarpa, S. Taxane induced neuropathy in patients affected by breast cancer: Literature review. Crit. Rev. Oncol. Hematol.,  2015, 96(1), 34-45.
[http://dx.doi.org/10.1016/j.critrevonc.2015.04.011] [PMID: 26004917] 
[20] 
McCracken, L.M. Social context and acceptance of chronic pain: the role of solicitous and punishing responses. Pain,  2005, 113(1-2), 155-159.
[http://dx.doi.org/10.1016/j.pain.2004.10.004] [PMID: 15621376] 
[21] 
Park, S.B.; Lin, C.S.Y.; Krishnan, A.V.; Friedlander, M.L.; Lewis, C.R.; Kiernan, M.C. Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle Nerve,  2011, 43(3), 367-374.
[http://dx.doi.org/10.1002/mus.21874] [PMID: 21321953] 
[22] 
Tofthagen, C.; McAllister, R.D.; Visovsky, C. Peripheral neuropathy caused by Paclitaxel and docetaxel: an evaluation and comparison of symptoms. J. Adv. Pract. Oncol.,  2013, 4(4), 204-215.
[PMID: 25032002] 
[23] 
Eckhoff, L.; Knoop, A.; Jensen, M.B.; Ewertz, M. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur. J. Cancer,  2015, 51(3), 292-300.
[http://dx.doi.org/10.1016/j.ejca.2014.11.024] [PMID: 25541155] 
[24] 
Bober, B.G.; Shah, S.B. Paclitaxel alters sensory nerve biomechanical properties. J. Biomech.,  2015, 48(13), 3559-3567.
[http://dx.doi.org/10.1016/j.jbiomech.2015.07.020] [PMID: 26321364] 
[25] 
LaPointe, N.E.; Morfini, G.; Brady, S.T.; Feinstein, S.C.; Wilson, L.; Jordan, M.A. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology,  2013, 37, 231-239.
[http://dx.doi.org/10.1016/j.neuro.2013.05.008] [PMID: 23711742] 
[26] 
Shemesh, O.A.; Spira, M.E. Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy. Acta Neuropathol.,  2010, 119(2), 235-248.
[http://dx.doi.org/10.1007/s00401-009-0586-0] [PMID: 19727778] 
[27] 
Boyette-Davis, J.; Xin, W.; Zhang, H.; Dougherty, P.M. Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain,  2011, 152(2), 308-313.
[http://dx.doi.org/10.1016/j.pain.2010.10.030] [PMID: 21145656] 
[28] 
Zajączkowska, R.; Kocot-Kępska, M.; Leppert, W.; Wrzosek, A.; Mika, J.; Wordliczek, J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci.,  2019, 20(6), 1451.
[http://dx.doi.org/10.3390/ijms20061451] [PMID: 30909387] 
[29] 
Siau, C.; Bennett, G.J. Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth. Analg.,  2006, 102(5), 1485-1490.
[http://dx.doi.org/10.1213/01.ane.0000204318.35194.ed] [PMID: 16632831] 
[30] 
Zhang, H.; Dougherty, P.M. Enhanced excitability of primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced peripheral neuropathy. Anesthesiology,  2014, 120(6), 1463-1475.
[http://dx.doi.org/10.1097/ALN.0000000000000176] [PMID: 24534904] 
[31] 
Areti, A.; Yerra, V.G.; Naidu, V.; Kumar, A. Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy. Redox Biol.,  2014, 2, 289-295.
[http://dx.doi.org/10.1016/j.redox.2014.01.006] [PMID: 24494204] 
[32] 
Doyle, T.; Chen, Z.; Muscoli, C.; Bryant, L.; Esposito, E.; Cuzzocrea, S.; Dagostino, C.; Ryerse, J.; Rausaria, S.; Kamadulski, A.; Neumann, W.L.; Salvemini, D. Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain. J. Neurosci.,  2012, 32(18), 6149-6160.
[http://dx.doi.org/10.1523/JNEUROSCI.6343-11.2012] [PMID: 22553021] 
[33] 
Zaks-Zilberman, M.; Zaks, T.Z.; Vogel, S.N. Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine,  2001, 15(3), 156-165.
[http://dx.doi.org/10.1006/cyto.2001.0935] [PMID: 11554785] 
[34] 
Hershman, D.L.; Lacchetti, C.; Dworkin, R.H.; Lavoie Smith, E.M.; Bleeker, J.; Cavaletti, G.; Chauhan, C.; Gavin, P.; Lavino, A.; Lustberg, M.B.; Paice, J.; Schneider, B.; Smith, M.L.; Smith, T.; Terstriep, S.; Wagner-Johnston, N.; Bak, K.; Loprinzi, C.L. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol.,  2014, 32(18), 1941-1967.
[http://dx.doi.org/10.1200/JCO.2013.54.0914] [PMID: 24733808] 
[35] 
Pachman, D.R.; Watson, J.C.; Lustberg, M.B.; Wagner-Johnston, N.D.; Chan, A.; Broadfield, L.; Cheung, Y.T.; Steer, C.; Storey, D.J.; Chandwani, K.D.; Paice, J.; Jean-Pierre, P.; Oh, J.; Kamath, J.; Fallon, M.; Strik, H.; Koeppen, S.; Loprinzi, C.L. Management options for established chemotherapy-induced peripheral neuropathy. Support. Care Cancer,  2014, 22(8), 2281-2295.
[http://dx.doi.org/10.1007/s00520-014-2289-x] [PMID: 24879391] 
[36] 
Smith, E.M.L.; Pang, H.; Cirrincione, C.; Fleishman, S.; Paskett, E.D.; Ahles, T.; Bressler, L.R.; Fadul, C.E.; Knox, C.; Le-Lindqwister, N.; Gilman, P.B.; Shapiro, C.L. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA,  2013, 309(13), 1359-1367.
[http://dx.doi.org/10.1001/jama.2013.2813] [PMID: 23549581] 
[37] 
Kundranda, M.N.; Niu, J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des. Devel. Ther.,  2015, 9, 3767-3777.
[http://dx.doi.org/10.2147/DDDT.S88023] [PMID: 26244011] 
[38] 
Carlson, K.; Ocean, A.J. Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin. Breast Cancer,  2011, 11(2), 73-81.
[http://dx.doi.org/10.1016/j.clbc.2011.03.006] [PMID: 21569993] 
[39] 
Gradishar, W.J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin. Pharmacother.,  2006, 7(8), 1041-1053.
[http://dx.doi.org/10.1517/14656566.7.8.1041] [PMID: 16722814] 
[40] 
Desai, A.V.; Marks, G.; Grunstein, R. Does sleep deprivation worsen mild obstructive sleep apnea? Sleep,  2003, 26(8), 1038-1041.
[http://dx.doi.org/10.1093/sleep/26.8.1038] [PMID: 14746387] 
[41] 
Framson, P.E.; Sage, E.H. SPARC and tumor growth: where the seed meets the soil? J. Cell. Biochem.,  2004, 92(4), 679-690.
[http://dx.doi.org/10.1002/jcb.20091] [PMID: 15211566] 
[42] 
Goldblum, S.E.; Ding, X.; Funk, S.E.; Sage, E.H. SPARC (secreted protein acidic and rich in cysteine) regulates endothelial cell shape and barrier function. Proc. Natl. Acad. Sci. USA,  1994, 91(8), 3448-3452.
[http://dx.doi.org/10.1073/pnas.91.8.3448] [PMID: 8159767] 
[43] 
Trieu, V.; Frankel, T.; Labao, E.; Soon-Shiong, P.; Desai, N. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol; AACR, 2005. 
[44] 
John, T.A.; Vogel, S.M.; Tiruppathi, C.; Malik, A.B.; Minshall, R.D. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am. J. Physiol. Lung Cell. Mol. Physiol.,  2003, 284(1), L187-L196.
[http://dx.doi.org/10.1152/ajplung.00152.2002] [PMID: 12471015] 
[45] 
Gradishar, W.J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O’Shaughnessy, J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol.,  2005, 23(31), 7794-7803.
[http://dx.doi.org/10.1200/JCO.2005.04.937] [PMID: 16172456] 
[46] 
Peng, L.; Bu, Z.; Ye, X.; Zhou, Y.; Zhao, Q. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis. Eur. J. Cancer Care (Engl.),  2017, 26(5), e12407.
[http://dx.doi.org/10.1111/ecc.12407] [PMID: 26537178] 
[47] 
Guo, X.; Sun, H.; Dong, J.; Feng, Y.; Li, H.; Zhuang, R.; Wang, P.; Cai, W.; Zhou, Y. Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol.,  2019, 139, 16-23.
[http://dx.doi.org/10.1016/j.critrevonc.2019.04.021] [PMID: 31112878] 
[48] 
Lee, J.J.; Swain, S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J. Clin. Oncol.,  2006, 24(10), 1633-1642.
[http://dx.doi.org/10.1200/JCO.2005.04.0543] [PMID: 16575015] 
[49] 
Swain, S.M.; Arezzo, J.C. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin. Adv. Hematol. Oncol.,  2008, 6(6), 455-467.
[PMID: 18567992] 
[50] 
Yamashita, Y.; Egashira, N.; Masuguchi, K.; Ushio, S.; Kawashiri, T.; Oishi, R. Comparison of peripheral neuropathy induced by standard and nanoparticle albumin-bound paclitaxel in rats. J. Pharmacol. Sci.,  2011, 117(2), 116-120.
[http://dx.doi.org/10.1254/jphs.11062SC] [PMID: 21897056] 
[51] 
Amptoulach, S; Tsavaris, N. Neurotoxicity caused by the treatment with platinum analogues. Chemotherapy Research and Practice, 2011.
[http://dx.doi.org/10.1155/2011/843019] 
[52] 
Mollman, J.E. Cisplatin neurotoxicity; Mass Medical Soc, 1990. 
[http://dx.doi.org/10.1056/NEJM199001113220210] 
[53] 
Prestayko, A.W.; D’Aoust, J.C.; Issell, B.F.; Crooke, S.T. Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat. Rev.,  1979, 6(1), 17-39.
[http://dx.doi.org/10.1016/S0305-7372(79)80057-2] [PMID: 378370] 
[54] 
Avan, A.; Postma, T.J.; Ceresa, C.; Avan, A.; Cavaletti, G.; Giovannetti, E.; Peters, G.J. Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist,  2015, 20(4), 411-432.
[http://dx.doi.org/10.1634/theoncologist.2014-0044] [PMID: 25765877] 
[55] 
Albers, JW; Chaudhry, V; Cavaletti, G; Donehower, RC Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database of Systematic Reviews, 2014, (3)
[http://dx.doi.org/10.1002/14651858.CD005228.pub4] 
[56] 
Starobova, H.; Vetter, I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front. Mol. Neurosci.,  2017, 10, 174.
[http://dx.doi.org/10.3389/fnmol.2017.00174] [PMID: 28620280] 
[57] 
Argyriou, A.A.; Bruna, J.; Marmiroli, P.; Cavaletti, G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit. Rev. Oncol. Hematol.,  2012, 82(1), 51-77.
[http://dx.doi.org/10.1016/j.critrevonc.2011.04.012] [PMID: 21908200] 
[58] 
Cavaletti, G. Chemotherapy-induced peripheral neurotoxicity (CIPN): what we need and what we know. J. Peripher. Nerv. Syst.,  2014, 19(2), 66-76.
[http://dx.doi.org/10.1111/jns5.12073] [PMID: 24976572] 
[59] 
Ip, V.; Liu, J.J.; McKeage, M.J. Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo. Clin. Exp. Pharmacol. Physiol.,  2013, 40(6), 371-378.
[http://dx.doi.org/10.1111/1440-1681.12088] [PMID: 23556474] 
[60] 
Liu, J.J.; Kim, Y.; Yan, F.; Ding, Q.; Ip, V.; Jong, N.N.; Mercer, J.F.; McKeage, M.J. Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons. Biochem. Pharmacol.,  2013, 85(2), 207-215.
[http://dx.doi.org/10.1016/j.bcp.2012.10.023] [PMID: 23123662] 
[61] 
Safaei, R.; Howell, S.B. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit. Rev. Oncol. Hematol.,  2005, 53(1), 13-23.
[http://dx.doi.org/10.1016/j.critrevonc.2004.09.007] [PMID: 15607932] 
[62] 
Zhu, C.; Raber, J.; Eriksson, L.A. Hydrolysis process of the second generation platinum-based anticancer drug cis-amminedichlorocyclohexylamineplatinum(II). J. Phys. Chem. B,  2005, 109(24), 12195-12205.
[http://dx.doi.org/10.1021/jp0518916] [PMID: 16852504] 
[63] 
Chválová, K.; Brabec, V.; Kaspárková, J. Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin. Nucleic Acids Res.,  2007, 35(6), 1812-1821.
[http://dx.doi.org/10.1093/nar/gkm032] [PMID: 17329374] 
[64] 
McDonald, E.S.; Randon, K.R.; Knight, A.; Windebank, A.J. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol. Dis.,  2005, 18(2), 305-313.
[http://dx.doi.org/10.1016/j.nbd.2004.09.013] [PMID: 15686959] 
[65] 
Meijer, C.; de Vries, E.G.; Marmiroli, P.; Tredici, G.; Frattola, L.; Cavaletti, G. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology,  1999, 20(6), 883-887.
[PMID: 10693969] 
[66] 
Dzagnidze, A.; Katsarava, Z.; Makhalova, J.; Liedert, B.; Yoon, M-S.; Kaube, H.; Limmroth, V.; Thomale, J. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J. Neurosci.,  2007, 27(35), 9451-9457.
[http://dx.doi.org/10.1523/JNEUROSCI.0523-07.2007] [PMID: 17728458] 
[67] 
Ta, L.E.; Espeset, L.; Podratz, J.; Windebank, A.J. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology,  2006, 27(6), 992-1002.
[http://dx.doi.org/10.1016/j.neuro.2006.04.010] [PMID: 16797073] 
[68] 
McWhinney, S.R.; Goldberg, R.M.; McLeod, H.L. Platinum neurotoxicity pharmacogenetics. Mol. Cancer Ther.,  2009, 8(1), 10-16.
[http://dx.doi.org/10.1158/1535-7163.MCT-08-0840] [PMID: 19139108] 
[69] 
Argyriou, A.A.; Polychronopoulos, P.; Iconomou, G.; Chroni, E.; Kalofonos, H.P. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat. Rev.,  2008, 34(4), 368-377.
[http://dx.doi.org/10.1016/j.ctrv.2008.01.003] [PMID: 18281158] 
[70] 
Neijt, J.P.; Engelholm, S.A.; Tuxen, M.K.; Sørensen, P.G.; Hansen, M.; Sessa, C.; de Swart, C.A.; Hirsch, F.R.; Lund, B.; van Houwelingen, H.C. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol.,  2000, 18(17), 3084-3092.
[http://dx.doi.org/10.1200/JCO.2000.18.17.3084] [PMID: 10963636] 
[71] 
Parmar, M.K.; Ledermann, J.A.; Colombo, N.; du Bois, A.; Delaloye, J.F.; Kristensen, G.B.; Wheeler, S.; Swart, A.M.; Qian, W.; Torri, V.; Floriani, I.; Jayson, G.; Lamont, A.; Tropé, C. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet,  2003, 361(9375), 2099-2106.
[http://dx.doi.org/10.1016/S0140-6736(03)13718-X] [PMID: 12826431] 
[72] 
Canetta, R.; Rozencweig, M.; Carter, S.K. Carboplatin: the clinical spectrum to date. Cancer Treat. Rev.,  1985, 12(Suppl. A), 125-136.
[http://dx.doi.org/10.1016/0305-7372(85)90027-1] [PMID: 3002623] 
[73] 
Kelley, M.R.; Jiang, Y.; Guo, C.; Reed, A.; Meng, H.; Vasko, M.R. Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy. PLoS One,  2014, 9(9), e106485.
[http://dx.doi.org/10.1371/journal.pone.0106485] [PMID: 25188410] 
[74] 
Chiorazzi, A.; Semperboni, S.; Marmiroli, P. Current view in platinum drug mechanisms of peripheral neurotoxicity. Toxics,  2015, 3(3), 304-321.
[http://dx.doi.org/10.3390/toxics3030304] [PMID: 29051466] 
[75] 
de Cos Escuín, JS; Delgado, IU; Rodríguez, JC; López, MJ; Vicente, CD; Miranda, JAR Stage IIIA and IIIB non-small cell lung cancer: results of chemotherapy combined with radiation therapy and analysis of prognostic factors. Archivos de Bronconeumología ((English Edition)),  2007, 43(7), 358-365.
[76] 
Helbekkmo, N.; Sundstrøm, S.H.; Aasebø, U.; Brunsvig, P.F.; von Plessen, C.; Hjelde, H.H.; Garpestad, O.K.; Bailey, A.; Bremnes, R.M. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br. J. Cancer,  2007, 97(3), 283-289.
[http://dx.doi.org/10.1038/sj.bjc.6603869] [PMID: 17595658] 
[77] 
Heinzlef, O.; Lotz, J-P.; Roullet, E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J. Neurol. Neurosurg. Psychiatry,  1998, 64(5), 667-669.
[http://dx.doi.org/10.1136/jnnp.64.5.667] [PMID: 9598687] 
[78] 
High-dose cisplatin therapy in ovarian cancer.Ozols, R.F.; Young, R.C., Eds.; Seminars in oncology; , 1985. 
[79] 
Roelofs, R.I.; Hrushesky, W.; Rogin, J.; Rosenberg, L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology,  1984, 34(7), 934-938.
[http://dx.doi.org/10.1212/WNL.34.7.934] [PMID: 6330613] 
[80] 
Thompson, S.W.; Davis, L.E.; Kornfeld, M.; Hilgers, R.D.; Standefer, J.C. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer,  1984, 54(7), 1269-1275.
[http://dx.doi.org/10.1002/1097-0142(19841001)54:7<1269::AID-CNCR2820540707>3.0.CO;2-9] [PMID: 6088023] 
[81] 
Krarup-Hansen, A.; Helweg-Larsen, S.; Schmalbruch, H.; Rørth, M.; Krarup, C. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain,  2007, 130(Pt 4), 1076-1088.
[http://dx.doi.org/10.1093/brain/awl356] [PMID: 17301082] 
[82] 
Von Hoff, D.D.; Schilsky, R.; Reichert, C.M.; Reddick, R.L.; Rozencweig, M.; Young, R.C.; Muggia, F.M. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat. Rep.,  1979, 63(9-10), 1527-1531.
[PMID: 387223] 
[83] 
Siegal, T.; Haim, N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer,  1990, 66(6), 1117-1123.
[http://dx.doi.org/10.1002/1097-0142(19900915)66:6<1117::AID-CNCR2820660607>3.0.CO;2-O] [PMID: 2169332] 
[84] 
Argyriou, A.A.; Cavaletti, G.; Briani, C.; Velasco, R.; Bruna, J.; Campagnolo, M.; Alberti, P.; Bergamo, F.; Cortinovis, D.; Cazzaniga, M.; Santos, C.; Papadimitriou, K.; Kalofonos, H.P. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer,  2013, 119(2), 438-444.
[http://dx.doi.org/10.1002/cncr.27732] [PMID: 22786764] 
[85] 
Pharmacokinetics and safety profile of oxaliplatin.Extra, J-M.; Marty, M.; Brienza, S.; Misset, J-L., Eds.; Seminars in oncology; , 1998. 
[86] 
Cersosimo, R.J. Cisplatin neurotoxicity. Cancer Treat. Rev.,  1989, 16(4), 195-211.
[http://dx.doi.org/10.1016/0305-7372(89)90041-8] [PMID: 2561592] 
[87] 
Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.Gamelin, E.; Gamelin, L.; Bossi, L.; Quasthoff, S., Eds.; Seminars in oncology; , 2002. 
[88] 
Cassidy, J.; Misset, J-L., Eds.; Oxaliplatin-related side effects: characteristics and management. Seminars in oncology; WB Saunders, 2002. 
[89] 
Saif, M.W.; Reardon, J. Management of oxaliplatin-induced peripheral neuropathy. Ther. Clin. Risk Manag.,  2005, 1(4), 249-258.
[PMID: 18360567] 
[90] 
Cavaletti, G.; Alberti, P.; Marmiroli, P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol.,  2011, 12(12), 1151-1161.
[http://dx.doi.org/10.1016/S1470-2045(11)70131-0] [PMID: 21719347] 
[91] 
Alejandro, L.M.; Behrendt, C.E.; Chen, K.; Openshaw, H.; Shibata, S. Predicting acute and persistent neuropathy associated with oxaliplatin. Am. J. Clin. Oncol.,  2013, 36(4), 331-337.
[http://dx.doi.org/10.1097/COC.0b013e318246b50d] [PMID: 22547012] 
[92] 
Alberti, P.; Rossi, E.; Cornblath, D.R.; Merkies, I.S.; Postma, T.J.; Frigeni, B.; Bruna, J.; Velasco, R.; Argyriou, A.A.; Kalofonos, H.P.; Psimaras, D.; Ricard, D.; Pace, A.; Galiè, E.; Briani, C.; Dalla Torre, C.; Faber, C.G.; Lalisang, R.I.; Boogerd, W.; Brandsma, D.; Koeppen, S.; Hense, J.; Storey, D.; Kerrigan, S.; Schenone, A.; Fabbri, S.; Valsecchi, M.G.; Cavaletti, G. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann. Oncol.,  2014, 25(1), 257-264.
[http://dx.doi.org/10.1093/annonc/mdt409] [PMID: 24256846] 
[93] 
Curcio, K.R. Instruments for Assessing Chemotherapy-Induced Peripheral Neuropathy: A Review of the Literature. Clin. J. Oncol. Nurs.,  2016, 20(2), 144-151.
[http://dx.doi.org/10.1188/16.CJON.20-01AP] [PMID: 26991707] 
[94] 
Kanat, O.; Ertas, H.; Caner, B. Platinum-induced neurotoxicity: A review of possible mechanisms. World J. Clin. Oncol.,  2017, 8(4), 329-335.
[http://dx.doi.org/10.5306/wjco.v8.i4.329] [PMID: 28848699] 
[95] 
Inoue, N.; Ishida, H.; Sano, M.; Kishino, T.; Okada, N.; Kumamoto, K.; Ishibashi, K. Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer. Int. J. Clin. Oncol.,  2012, 17(4), 341-347.
[http://dx.doi.org/10.1007/s10147-011-0298-z] [PMID: 21833683] 
[96] 
Verstappen, C.C.; Heimans, J.J.; Hoekman, K.; Postma, T.J. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs,  2003, 63(15), 1549-1563.
[http://dx.doi.org/10.2165/00003495-200363150-00003] [PMID: 12887262] 
[97] 
Hill, A.; Bergin, P.; Hanning, F.; Thompson, P.; Findlay, M.; Damianovich, D.; McKeage, M.J. Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. BMC Cancer,  2010, 10(1), 451.
[http://dx.doi.org/10.1186/1471-2407-10-451] [PMID: 20731872] 
[98] 
Park, S.B.; Lin, C.S-Y.; Krishnan, A.V.; Goldstein, D.; Friedlander, M.L.; Kiernan, M.C. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain,  2009, 132(Pt 10), 2712-2723.
[http://dx.doi.org/10.1093/brain/awp219] [PMID: 19745023] 
[99] 
Yang, L.; Yu, L.; Chen, X.; Hu, Y.; Wang, B. Clinical analysis of adverse drug reactions between vincristine and triazoles in children with acute lymphoblastic leukemia. Med. Sci. Monit.,  2015, 21, 1656-1661.
[http://dx.doi.org/10.12659/MSM.893142] [PMID: 26050202] 
[100] 
Gidding, C.E.; Kellie, S.J.; Kamps, W.A.; de Graaf, S.S. Vincristine revisited. Crit. Rev. Oncol. Hematol.,  1999, 29(3), 267-287.
[http://dx.doi.org/10.1016/S1040-8428(98)00023-7] [PMID: 10226730] 
[101] 
Gan, P.P.; McCarroll, J.A.; Po’uha, S.T.; Kamath, K.; Jordan, M.A.; Kavallaris, M. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol. Cancer Ther.,  2010, 9(5), 1339-1348.
[http://dx.doi.org/10.1158/1535-7163.MCT-09-0679] [PMID: 20442307] 
[102] 
Gutierrez-Camino, Á.; Umerez, M.; Martin-Guerrero, I.; García de Andoin, N.; Santos, B.; Sastre, A.; Echebarria-Barona, A.; Astigarraga, I.; Navajas, A.; Garcia-Orad, A. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia. Pharmacogenomics J.,  2018, 18(6), 704-712.
[http://dx.doi.org/10.1038/s41397-017-0003-3] [PMID: 29282364] 
[103] 
Chan, S.Y.; Worth, R.; Ochs, S. Block of axoplasmic transport in vitro by vinca alkaloids. J. Neurobiol.,  1980, 11(3), 251-264.
[http://dx.doi.org/10.1002/neu.480110304] [PMID: 6156229] 
[104] 
Devor, M. Sodium channels and mechanisms of neuropathic pain. J. Pain,  2006, 7(1)(Suppl. 1), S3-S12.
[http://dx.doi.org/10.1016/j.jpain.2005.09.006] [PMID: 16426998] 
[105] 
Boehmerle, W.; Huehnchen, P.; Peruzzaro, S.; Balkaya, M.; Endres, M. Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice. Sci. Rep.,  2014, 4, 6370.
[http://dx.doi.org/10.1038/srep06370] [PMID: 25231679] 
[106] 
Carozzi, V.A.; Canta, A.; Chiorazzi, A. Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? Neurosci. Lett.,  2015, 596, 90-107.
[http://dx.doi.org/10.1016/j.neulet.2014.10.014] [PMID: 25459280] 
[107] 
Lavoie Smith, E.M.; Li, L.; Chiang, C.; Thomas, K.; Hutchinson, R.J.; Wells, E.M.; Ho, R.H.; Skiles, J.; Chakraborty, A.; Bridges, C.M.; Renbarger, J. Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. J. Peripher. Nerv. Syst.,  2015, 20(1), 37-46.
[http://dx.doi.org/10.1111/jns.12114] [PMID: 25977177] 
[108] 
Kavcic, M.; Koritnik, B.; Krzan, M.; Velikonja, O.; Prelog, T.; Stefanovic, M.; Debeljak, M.; Jazbec, J. Electrophysiological studies to detect peripheral neuropathy in children treated with vincristine. J. Pediatr. Hematol. Oncol.,  2017, 39(4), 266-271.
[http://dx.doi.org/10.1097/MPH.0000000000000825] [PMID: 28375940] 
[109] 
Haim, N.; Epelbaum, R.; Ben-Shahar, M.; Yarnitsky, D.; Simri, W.; Robinson, E. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer,  1994, 73(10), 2515-2519.
[http://dx.doi.org/10.1002/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G] [PMID: 8174048] 
[110] 
Barton, D.L.; Wos, E.J.; Qin, R.; Mattar, B.I.; Green, N.B.; Lanier, K.S.; Bearden, J.D., III; Kugler, J.W.; Hoff, K.L.; Reddy, P.S.; Rowland, K.M., Jr; Riepl, M.; Christensen, B.; Loprinzi, C.L. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support. Care Cancer,  2011, 19(6), 833-841.
[http://dx.doi.org/10.1007/s00520-010-0911-0] [PMID: 20496177] 
[111] 
Mora, E.; Smith, E.M.L.; Donohoe, C.; Hertz, D.L. Vincristine-induced peripheral neuropathy in pediatric cancer patients. Am. J. Cancer Res.,  2016, 6(11), 2416-2430.
[PMID: 27904761] 
[112] 
El Hayek, M.; Trad, O.; Jamil, A. Vincristine-induced urinary bladder paralysis. J. Pediatr. Hematol. Oncol.,  2005, 27(5), 286-287.
[http://dx.doi.org/10.1097/01.mph.0000165130.21539.a3] [PMID: 15891567] 
[113] 
Lee, D.H.; Goldberg, A.L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol.,  1998, 8(10), 397-403.
[http://dx.doi.org/10.1016/S0962-8924(98)01346-4] [PMID: 9789328] 
[114] 
Moreau, P.; Karamanesht, I.I.; Domnikova, N.; Kyselyova, M.Y.; Vilchevska, K.V.; Doronin, V.A.; Schmidt, A.; Hulin, C.; Leleu, X.; Esseltine, D.L.; Venkatakrishnan, K.; Skee, D.; Feng, H.; Girgis, S.; Cakana, A.; van de Velde, H.; Deraedt, W.; Facon, T. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin. Pharmacokinet.,  2012, 51(12), 823-829.
[http://dx.doi.org/10.1007/s40262-012-0010-0] [PMID: 23018466] 
[115] 
Delforge, M.; Bladé, J.; Dimopoulos, M.A.; Facon, T.; Kropff, M.; Ludwig, H.; Palumbo, A.; Van Damme, P.; San-Miguel, J.F.; Sonneveld, P. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol.,  2010, 11(11), 1086-1095.
[http://dx.doi.org/10.1016/S1470-2045(10)70068-1] [PMID: 20932799] 
[116] 
Crawford, L.J.; Walker, B.; Ovaa, H.; Chauhan, D.; Anderson, K.C.; Morris, T.C.; Irvine, A.E. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res.,  2006, 66(12), 6379-6386.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-0605] [PMID: 16778216] 
[117] 
Łuczkowska, K.; Litwińska, Z.; Paczkowska, E.; Machaliński, B. Pathophysiology of drug-induced peripheral neuropathy in multiple myeloma patients. J. Physiol. Pharmacol.,  2018, 69, 165-172.
[118] 
Kaplan, G.S.; Torcun, C.C.; Grune, T.; Ozer, N.K.; Karademir, B. Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect. Free Radic. Biol. Med.,  2017, 103, 1-13.
[http://dx.doi.org/10.1016/j.freeradbiomed.2016.12.007] [PMID: 27940347] 
[119] 
Velasco, R.; Petit, J.; Clapés, V.; Verdú, E.; Navarro, X.; Bruna, J. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J. Peripher. Nerv. Syst.,  2010, 15(1), 17-25.
[http://dx.doi.org/10.1111/j.1529-8027.2010.00248.x] [PMID: 20433602] 
[120] 
Lakshman, A; Modi, M; Prakash, G; Malhotra, P; Khadwal, A; Jain, S Evaluation of bortezomib-induced neuropathy using total neuropathy score (reduced and clinical versions) and NCI CTCAE v4. 0 in newly diagnosed patients with multiple myeloma receiving bortezomib-based induction. Clinical Lymphoma Myeloma and Leukemia,  2017, 17(8), 513-519.
[121] 
Landowski, T.H.; Megli, C.J.; Nullmeyer, K.D.; Lynch, R.M.; Dorr, R.T. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res.,  2005, 65(9), 3828-3836.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-3684] [PMID: 15867381] 
[122] 
Hideshima, T.; Ikeda, H.; Chauhan, D.; Okawa, Y.; Raje, N.; Podar, K.; Mitsiades, C.; Munshi, N.C.; Richardson, P.G.; Carrasco, R.D.; Anderson, K.C. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood,  2009, 114(5), 1046-1052.
[http://dx.doi.org/10.1182/blood-2009-01-199604] [PMID: 19436050] 
[123] 
Azoulay, D.; Lavie, D.; Horowitz, N.; Suriu, C.; Gatt, M.E.; Akria, L.; Perlman, R.; Braester, A.; Ben-Yehuda, D. Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma. Br. J. Haematol.,  2014, 164(3), 454-456.
[http://dx.doi.org/10.1111/bjh.12624] [PMID: 24164472] 
[124] 
Broyl, A.; Corthals, S.L.; Jongen, J.L.; van der Holt, B.; Kuiper, R.; de Knegt, Y.; van Duin, M.; el Jarari, L.; Bertsch, U.; Lokhorst, H.M.; Durie, B.G.; Goldschmidt, H.; Sonneveld, P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol.,  2010, 11(11), 1057-1065.
[http://dx.doi.org/10.1016/S1470-2045(10)70206-0] [PMID: 20864405] 
[125] 
Meregalli, C.; Canta, A.; Carozzi, V.A.; Chiorazzi, A.; Oggioni, N.; Gilardini, A.; Ceresa, C.; Avezza, F.; Crippa, L.; Marmiroli, P.; Cavaletti, G. Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur. J. Pain,  2010, 14(4), 343-350.
[http://dx.doi.org/10.1016/j.ejpain.2009.07.001] [PMID: 19695912] 
[126] 
Meregalli, C.; Ceresa, C.; Canta, A.; Carozzi, V.A.; Chiorazzi, A.; Sala, B.; Oggioni, N.; Lanza, M.; Letari, O.; Ferrari, F.; Avezza, F.; Marmiroli, P.; Caselli, G.; Cavaletti, G. CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. J. Pain Res.,  2012, 5, 151-167.
[PMID: 22792002] 
[127] 
Casafont, I.; Berciano, M.T.; Lafarga, M. Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox. Res.,  2010, 17(2), 167-178.
[http://dx.doi.org/10.1007/s12640-009-9086-1] [PMID: 19609631] 
[128] 
Cavaletti, G.; Gilardini, A.; Canta, A.; Rigamonti, L.; Rodriguez-Menendez, V.; Ceresa, C.; Marmiroli, P.; Bossi, M.; Oggioni, N.; D’Incalci, M.; De Coster, R. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp. Neurol.,  2007, 204(1), 317-325.
[http://dx.doi.org/10.1016/j.expneurol.2006.11.010] [PMID: 17214983] 
[129] 
Meregalli, C.; Canta, A.; Chiorazzi, A.; Gilardini, A. RODRIGUEZ MENENDEZ V Annual Meeting of the Peripheral-Nerve-Society, 2009.
[130] 
Ravaglia, S.; Corso, A.; Piccolo, G.; Lozza, A.; Alfonsi, E.; Mangiacavalli, S.; Varettoni, M.; Zappasodi, P.; Moglia, A.; Lazzarino, M.; Costa, A. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin. Neurophysiol.,  2008, 119(11), 2507-2512.
[http://dx.doi.org/10.1016/j.clinph.2008.08.007] [PMID: 18829381] 
[131] 
Jaggi, A.S.; Singh, N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology,  2012, 291(1-3), 1-9.
[http://dx.doi.org/10.1016/j.tox.2011.10.019] [PMID: 22079234] 
[132] 
Wang, H; Liu, Z; Yang, W; Liao, A; Zhang, R; Wu, B Study on mechanism of bortezomib inducing peripheral neuropathy and the reversing effect of reduced glutathione. Zhonghua xue ye xue za zhi= Zhonghua xueyexue zazhi,  2011, 32(2), 107-111.
[133] 
Dick, L.R.; Fleming, P.E. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov. Today,  2010, 15(5-6), 243-249.
[http://dx.doi.org/10.1016/j.drudis.2010.01.008] [PMID: 20116451] 
[134] 
Saifee, T.A.; Elliott, K.J.; Rabin, N.; Yong, K.L.; D’Sa, S.; Brandner, S.; Lunn, M.P.; Blake, J.; Reilly, M.M. Bortezomib-induced inflammatory neuropathy. J. Peripher. Nerv. Syst.,  2010, 15(4), 366-368.
[http://dx.doi.org/10.1111/j.1529-8027.2010.00287.x] [PMID: 21199108] 
[135] 
Thawani, S.P.; Tanji, K.; De Sousa, E.A.; Weimer, L.H.; Brannagan, T.H., III Bortezomib-associated demyelinating neuropathy--clinical and pathologic features. J. Clin. Neuromuscul. Dis.,  2015, 16(4), 202-209.
[http://dx.doi.org/10.1097/CND.0000000000000077] [PMID: 25996966] 
[136] 
Windebank, A.J.; Grisold, W. Chemotherapy-induced neuropathy. J. Peripher. Nerv. Syst.,  2008, 13(1), 27-46.
[http://dx.doi.org/10.1111/j.1529-8027.2008.00156.x] [PMID: 18346229] 
[137] 
Argyriou, A.A.; Cavaletti, G.; Bruna, J.; Kyritsis, A.P.; Kalofonos, H.P. Bortezomib-induced peripheral neurotoxicity: an update. Arch. Toxicol.,  2014, 88(9), 1669-1679.
[http://dx.doi.org/10.1007/s00204-014-1316-5] [PMID: 25069804] 
[138] 
Lanzani, F.; Mattavelli, L.; Frigeni, B.; Rossini, F.; Cammarota, S.; Petrò, D.; Jann, S.; Cavaletti, G. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J. Peripher. Nerv. Syst.,  2008, 13(4), 267-274.
[http://dx.doi.org/10.1111/j.1529-8027.2008.00192.x] [PMID: 19192066] 
[139] 
Stratogianni, A.; Tosch, M.; Schlemmer, H.; Weis, J.; Katona, I.; Isenmann, S.; Haensch, C.A. Bortezomib-induced severe autonomic neuropathy. Clin. Auton. Res.,  2012, 22(4), 199-202.
[http://dx.doi.org/10.1007/s10286-012-0164-8] [PMID: 22532274] 
[140] 
Giannoccaro, M.P.; Donadio, V.; Gomis Pèrez, C.; Borsini, W.; Di Stasi, V.; Liguori, R. Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study. Neurol. Sci.,  2011, 32(2), 361-363.
[http://dx.doi.org/10.1007/s10072-010-0475-2] [PMID: 21290160] 
[141] 
Favis, R.; Sun, Y.; van de Velde, H.; Broderick, E.; Levey, L.; Meyers, M.; Mulligan, G.; Harousseau, J.L.; Richardson, P.G.; Ricci, D.S. Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet. Genomics,  2011, 21(3), 121-129.
[http://dx.doi.org/10.1097/FPC.0b013e3283436b45] [PMID: 21228734] 
[142] 
Corthals, S.L.; Kuiper, R.; Johnson, D.C.; Sonneveld, P.; Hajek, R.; van der Holt, B.; Magrangeas, F.; Goldschmidt, H.; Morgan, G.J.; Avet-Loiseau, H. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica,  2011, 96(11), 1728-1732.
[http://dx.doi.org/10.3324/haematol.2011.041434] [PMID: 21791469] 
[143] 
Badros, A.; Goloubeva, O.; Dalal, J.S.; Can, I.; Thompson, J.; Rapoport, A.P.; Heyman, M.; Akpek, G.; Fenton, R.G. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer,  2007, 110(5), 1042-1049.
[http://dx.doi.org/10.1002/cncr.22921] [PMID: 17654660] 
[144] 
Stubblefield, M.D.; McNeely, M.L.; Alfano, C.M.; Mayer, D.K. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy. Cancer,  2012, 118(8)(Suppl.), 2250-2260.
[http://dx.doi.org/10.1002/cncr.27463] [PMID: 22488699] 
[145] 
Kanbayashi, Y.; Hosokawa, T.; Okamoto, K.; Konishi, H.; Otsuji, E.; Yoshikawa, T.; Takagi, T.; Taniwaki, M. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Anticancer Drugs,  2010, 21(9), 877-881.
[http://dx.doi.org/10.1097/CAD.0b013e32833db89d] [PMID: 20679888] 
[146] 
Wang, L.; Wang, K-F.; Chang, B-Y.; Chen, X-Q.; Xia, Z-J. Once-weekly subcutaneous administration of bortezomib in patients with multiple myeloma. Asian Pac. J. Cancer Prev.,  2015, 16(5), 2093-2098.
[http://dx.doi.org/10.7314/APJCP.2015.16.5.2093] [PMID: 25773856] 
[147] 
Richardson, P.G.; Xie, W.; Mitsiades, C.; Chanan-Khan, A.A.; Lonial, S.; Hassoun, H.; Avigan, D.E.; Oaklander, A.L.; Kuter, D.J.; Wen, P.Y.; Kesari, S.; Briemberg, H.R.; Schlossman, R.L.; Munshi, N.C.; Heffner, L.T.; Doss, D.; Esseltine, D.L.; Weller, E.; Anderson, K.C.; Amato, A.A. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J. Clin. Oncol.,  2009, 27(21), 3518-3525.
[http://dx.doi.org/10.1200/JCO.2008.18.3087] [PMID: 19528374] 
[148] 
Argyriou, A.A.; Iconomou, G.; Kalofonos, H.P. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood,  2008, 112(5), 1593-1599.
[http://dx.doi.org/10.1182/blood-2008-04-149385] [PMID: 18574024] 
[149] 
Oken, M.M.; Creech, R.H.; Tormey, D.C.; Horton, J.; Davis, T.E.; McFadden, E.T.; Carbone, P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol.,  1982, 5(6), 649-655.
[http://dx.doi.org/10.1097/00000421-198212000-00014] [PMID: 7165009] 
[150] 
Ajani, J.A.; Welch, S.R.; Raber, M.N.; Fields, W.S.; Krakoff, I.H. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest.,  1990, 8(2), 147-159.
[http://dx.doi.org/10.3109/07357909009017560] [PMID: 2400936] 
[151] 
Miller, A; Hoogstraten, B; Staquet, M; Winkler, A Reporting results of cancer treatment. cancer,  1981, 47(1), 207-214.
[152] 
Nicolini, G.; Monfrini, M.; Scuteri, A. Axonal transport impairment in chemotherapy-induced peripheral neuropathy. Toxics,  2015, 3(3), 322-341.
[http://dx.doi.org/10.3390/toxics3030322] [PMID: 29051467] 
[153] 
Lee, J.J.; Swain, S.M., Eds.; Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Seminars in oncology; Elsevier, 2005. 
[154] 
Steinberg, M. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer. Clin. Ther.,  2008, 30(9), 1590-1617.
[http://dx.doi.org/10.1016/j.clinthera.2008.09.015] [PMID: 18840366] 
[155] 
Hoffmann, J.; Vitale, I.; Buchmann, B.; Galluzzi, L.; Schwede, W.; Senovilla, L.; Skuballa, W.; Vivet, S.; Lichtner, R.B.; Vicencio, J.M.; Panaretakis, T.; Siemeister, G.; Lage, H.; Nanty, L.; Hammer, S.; Mittelstaedt, K.; Winsel, S.; Eschenbrenner, J.; Castedo, M.; Demarche, C.; Klar, U.; Kroemer, G. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res.,  2008, 68(13), 5301-5308.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-0237] [PMID: 18593931] 
[156] 
Klar, U.; Buchmann, B.; Schwede, W.; Skuballa, W.; Hoffmann, J.; Lichtner, R.B. Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew. Chem. Int. Ed. Engl.,  2006, 45(47), 7942-7948.
[http://dx.doi.org/10.1002/anie.200602785] [PMID: 17006870] 
[157] 
Argyriou, A.A.; Marmiroli, P.; Cavaletti, G.; Kalofonos, H.P. Epothilone-induced peripheral neuropathy: a review of current knowledge. J. Pain Symptom Manage.,  2011, 42(6), 931-940.
[http://dx.doi.org/10.1016/j.jpainsymman.2011.02.022] [PMID: 21621965] 
[158] 
Vahdat, L.T.; Thomas, E.S.; Roché, H.H.; Hortobagyi, G.N.; Sparano, J.A.; Yelle, L.; Fornier, M.N.; Martín, M.; Bunnell, C.A.; Mukhopadhyay, P.; Peck, R.A.; Perez, E.A. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support. Care Cancer,  2012, 20(11), 2661-2668.
[http://dx.doi.org/10.1007/s00520-012-1384-0] [PMID: 22382588] 
[159] 
Cavaletti, G.; Marmiroli, P. Chemotherapy-induced peripheral neurotoxicity. Nat. Rev. Neurol.,  2010, 6(12), 657-666.
[http://dx.doi.org/10.1038/nrneurol.2010.160] [PMID: 21060341] 
[160] 
Cioroiu, C.; Weimer, L.H. Update on chemotherapy-induced peripheral neuropathy. Curr. Neurol. Neurosci. Rep.,  2017, 17(6), 47.
[http://dx.doi.org/10.1007/s11910-017-0757-7] [PMID: 28421360] 
[161] 
Cortes, J.; O’Shaughnessy, J.; Loesch, D.; Blum, J.L.; Vahdat, L.T.; Petrakova, K.; Chollet, P.; Manikas, A.; Diéras, V.; Delozier, T.; Vladimirov, V.; Cardoso, F.; Koh, H.; Bougnoux, P.; Dutcus, C.E.; Seegobin, S.; Mir, D.; Meneses, N.; Wanders, J.; Twelves, C. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet,  2011, 377(9769), 914-923.
[http://dx.doi.org/10.1016/S0140-6736(11)60070-6] [PMID: 21376385] 
[162] 
Twelves, C.; Cortes, J.; Vahdat, L.; Olivo, M.; He, Y.; Kaufman, P.A.; Awada, A. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res. Treat.,  2014, 148(3), 553-561.
[http://dx.doi.org/10.1007/s10549-014-3144-y] [PMID: 25381136] 
[163] 
Wozniak, K.M.; Vornov, J.J.; Wu, Y.; Liu, Y.; Carozzi, V.A.; Rodriguez-Menendez, V.; Ballarini, E.; Alberti, P.; Pozzi, E.; Semperboni, S.; Cook, B.M.; Littlefield, B.A.; Nomoto, K.; Condon, K.; Eckley, S.; DesJardins, C.; Wilson, L.; Jordan, M.A.; Feinstein, S.C.; Cavaletti, G.; Polydefkis, M.; Slusher, B.S. Peripheral neuropathy induced by microtubule-targeted chemotherapies: insights into acute injury and long-term recovery. Cancer Res.,  2018, 78(3), 817-829.
[http://dx.doi.org/10.1158/0008-5472.CAN-17-1467] [PMID: 29191802] 
[164] 
Okouneva, T.; Azarenko, O.; Wilson, L.; Littlefield, B.A.; Jordan, M.A. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther.,  2008, 7(7), 2003-2011.
[http://dx.doi.org/10.1158/1535-7163.MCT-08-0095] [PMID: 18645010] 
[165] 
Jordan, M.A.; Kamath, K.; Manna, T.; Okouneva, T.; Miller, H.P.; Davis, C.; Littlefield, B.A.; Wilson, L. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther.,  2005, 4(7), 1086-1095.
[http://dx.doi.org/10.1158/1535-7163.MCT-04-0345] [PMID: 16020666] 
[166] 
Kannarkat, G.; Lasher, E.E.; Schiff, D. Neurologic complications of chemotherapy agents. Curr. Opin. Neurol.,  2007, 20(6), 719-725.
[http://dx.doi.org/10.1097/WCO.0b013e3282f1a06e] [PMID: 17992096] 
[167] 
Visovsky, C. Chemotherapy-induced peripheral neuropathy. Cancer Invest.,  2003, 21(3), 439-451.
[http://dx.doi.org/10.1081/CNV-120018236] [PMID: 12901290] 
[168] 
Ansell, S.M. Brentuximab vedotin. Blood,  2014, 124(22), 3197-3200.
[http://dx.doi.org/10.1182/blood-2014-06-537514] [PMID: 25293772] 
[169] 
Connors, J.M.; Jurczak, W.; Straus, D.J.; Ansell, S.M.; Kim, W.S.; Gallamini, A.; Younes, A.; Alekseev, S.; Illés, Á.; Picardi, M.; Lech-Maranda, E.; Oki, Y.; Feldman, T.; Smolewski, P.; Savage, K.J.; Bartlett, N.L.; Walewski, J.; Chen, R.; Ramchandren, R.; Zinzani, P.L.; Cunningham, D.; Rosta, A.; Josephson, N.C.; Song, E.; Sachs, J.; Liu, R.; Jolin, H.A.; Huebner, D.; Radford, J. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N. Engl. J. Med.,  2018, 378(4), 331-344.
[http://dx.doi.org/10.1056/NEJMoa1708984] [PMID: 29224502] 
[170] 
Horwitz, S.; O’Connor, O.A.; Pro, B.; Illidge, T.; Fanale, M.; Advani, R.; Bartlett, N.L.; Christensen, J.H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; Kim, W.S.; Feldman, T.; Lennard, A.; Belada, D.; Illés, Á.; Tobinai, K.; Tsukasaki, K.; Yeh, S.P.; Shustov, A.; Hüttmann, A.; Savage, K.J.; Yuen, S.; Iyer, S.; Zinzani, P.L.; Hua, Z.; Little, M.; Rao, S.; Woolery, J.; Manley, T.; Trümper, L. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet,  2019, 393(10168), 229-240.
[http://dx.doi.org/10.1016/S0140-6736(18)32984-2] [PMID: 30522922] 
[171] 
Deng, C.; Pan, B.; O’Connor, O.A. Brentuximab vedotin. Clin. Cancer Res.,  2013, 19(1), 22-27.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-0290] [PMID: 23155186] 
[172] 
Smith, C.A.; Gruss, H-J.; Davis, T.; Anderson, D.; Farrah, T.; Baker, E.; Sutherland, G.R.; Brannan, C.I.; Copeland, N.G.; Jenkins, N.A. CD30 antigen, a marker for Hodgkin’s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell,  1993, 73(7), 1349-1360.
[http://dx.doi.org/10.1016/0092-8674(93)90361-S] [PMID: 8391931] 
[173] 
Aggarwal, B.B.; Gupta, S.C.; Kim, J.H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood,  2012, 119(3), 651-665.
[http://dx.doi.org/10.1182/blood-2011-04-325225] [PMID: 22053109] 
[174] 
Sutherland, M.S.K.; Sanderson, R.J.; Gordon, K.A.; Andreyka, J.; Cerveny, C.G.; Yu, C.; Lewis, T.S.; Meyer, D.L.; Zabinski, R.F.; Doronina, S.O.; Senter, P.D.; Law, C.L.; Wahl, A.F. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J. Biol. Chem.,  2006, 281(15), 10540-10547.
[http://dx.doi.org/10.1074/jbc.M510026200] [PMID: 16484228] 
[175] 
Okeley, N.M.; Miyamoto, J.B.; Zhang, X.; Sanderson, R.J.; Benjamin, D.R.; Sievers, E.L.; Senter, P.D.; Alley, S.C. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin. Cancer Res.,  2010, 16(3), 888-897.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-2069] [PMID: 20086002] 
[176] 
Fromm, J.R.; McEarchern, J.A.; Kennedy, D.; Thomas, A.; Shustov, A.R.; Gopal, A.K. Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms. Clin. Lymphoma Myeloma Leuk.,  2012, 12(4), 280-283.
[http://dx.doi.org/10.1016/j.clml.2012.01.012] [PMID: 22542449] 
[177] 
Mariotto, S.; Tecchio, C.; Sorio, M.; Bertolasi, L.; Turatti, M.; Tozzi, M.C.; Benedetti, F.; Cavaletti, G.; Monaco, S.; Ferrari, S. Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy. Leuk. Lymphoma,  2019, 60(11), 2806-2809.
[http://dx.doi.org/10.1080/10428194.2019.1605068] [PMID: 31057013] 
[178] 
Corbin, Z.A.; Nguyen-Lin, A.; Li, S.; Rahbar, Z.; Tavallaee, M.; Vogel, H.; Salva, K.A.; Wood, G.S.; Kim, Y.H.; Nagpal, S. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. J. Neurooncol.,  2017, 132(3), 439-446.
[http://dx.doi.org/10.1007/s11060-017-2389-9] [PMID: 28271282] 
[179] 
Suri, A.; Mould, D.R.; Song, G.; Collins, G.P.; Endres, C.J.; Gomez-Navarro, J.; Venkatakrishnan, K. Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin’s Lymphoma in the Phase III ECHELON-1 Study. Clin. Pharmacol. Ther.,  2019, 106(6), 1268-1279.
[http://dx.doi.org/10.1002/cpt.1530] [PMID: 31152605] 
[180] 
Mariotto, S; Ferrari, S; Sorio, M; Benedetti, F; Tridente, G; Cavallaro, T Brentuximab vedotin: axonal microtubule’s Apollyon. Blood cancer journal,  2015, 5(8), e343.
[http://dx.doi.org/10.1038/bcj.2015.72] 
[181] 
McGeary, R.P.; Bennett, A.J.; Tran, Q.B.; Cosgrove, K.L.; Ross, B.P. Suramin: clinical uses and structure-activity relationships. Mini Rev. Med. Chem.,  2008, 8(13), 1384-1394.
[http://dx.doi.org/10.2174/138955708786369573] [PMID: 18991754] 
[182] 
De Clercq, E. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett.,  1979, 8(1), 9-22.
[http://dx.doi.org/10.1016/0304-3835(79)90017-X] [PMID: 92362] 
[183] 
Broder, S.; Yarchoan, R.; Collins, J.M.; Lane, H.C.; Markham, P.D.; Klecker, R.W.; Redfield, R.R.; Mitsuya, H.; Hoth, D.F.; Gelmann, E. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi’s sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet,  1985, 2(8456), 627-630.
[http://dx.doi.org/10.1016/S0140-6736(85)90002-9] [PMID: 2863631] 
[184] 
Eisenberger, M.A.; Reyno, L.M.; Jodrell, D.I.; Sinibaldi, V.J.; Tkaczuk, K.H.; Sridhara, R.; Zuhowski, E.G.; Lowitt, M.H.; Jacobs, S.C.; Egorin, M.J. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J. Natl. Cancer Inst.,  1993, 85(8), 611-621.
[http://dx.doi.org/10.1093/jnci/85.8.611] [PMID: 8468719] 
[185] 
Myers, C.; Cooper, M.; Stein, C.; LaRocca, R.; Walther, M.M.; Weiss, G.; Choyke, P.; Dawson, N.; Steinberg, S.; Uhrich, M.M. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J. Clin. Oncol.,  1992, 10(6), 881-889.
[http://dx.doi.org/10.1200/JCO.1992.10.6.881] [PMID: 1375283] 
[186] 
Chaudhry, V.; Eisenberger, M.A.; Sinibaldi, V.J.; Sheikh, K.; Griffin, J.W.; Cornblath, D.R. A prospective study of suramin-induced peripheral neuropathy. Brain,  1996, 119(Pt 6), 2039-2052.
[http://dx.doi.org/10.1093/brain/119.6.2039] [PMID: 9010008] 
[187] 
Russell, J.W.; Gill, J.S.; Sorenson, E.J.; Schultz, D.A.; Windebank, A.J. Suramin-induced neuropathy in an animal model. J. Neurol. Sci.,  2001, 192(1-2), 71-80.
[http://dx.doi.org/10.1016/S0022-510X(01)00633-5] [PMID: 11701155] 
[188] 
Constantopoulos, G.; Rees, S.; Cragg, B.G.; Barranger, J.A.; Brady, R.O. Effect of suramin on the activities of degradative enzymes of sphingolipids in rats. Res. Commun. Chem. Pathol. Pharmacol.,  1981, 32(1), 87-97.
[PMID: 7291729] 
[189] 
Quasthoff, S.; Hartung, H.P. Chemotherapy-induced peripheral neuropathy. J. Neurol.,  2002, 249(1), 9-17.
[http://dx.doi.org/10.1007/PL00007853] [PMID: 11954874] 
[190] 
Voogd, T.E.; Vansterkenburg, E.L.; Wilting, J.; Janssen, L.H. Recent research on the biological activity of suramin. Pharmacol. Rev.,  1993, 45(2), 177-203.
[PMID: 8396782] 
[191] 
Peltier, A.C.; Russell, J.W. Recent advances in drug-induced neuropathies. Curr. Opin. Neurol.,  2002, 15(5), 633-638.
[http://dx.doi.org/10.1097/00019052-200210000-00015] [PMID: 12352008] 
[192] 
Gill, J.S.; Windebank, A.J. Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons. Cell Death Differ.,  1998, 5(10), 876-883.
[http://dx.doi.org/10.1038/sj.cdd.4400410] [PMID: 10203686] 
[193] 
Gill, J.S.; Hobday, K.L.; Windebank, A.J. Mechanism of suramin toxicity in stable myelinating dorsal root ganglion cultures. Exp. Neurol.,  1995, 133(2), 113-124.
[http://dx.doi.org/10.1006/exnr.1995.1014] [PMID: 7649218] 
[194] 
Mayer, C.; Quasthoff, S.; Grafe, P. Differences in the sensitivity to purinergic stimulation of myelinating and non-myelinating Schwann cells in peripheral human and rat nerve. Glia,  1998, 23(4), 374-382.
[http://dx.doi.org/10.1002/(SICI)1098-1136(199808)23:4<374::AID-GLIA9>3.0.CO;2-2] [PMID: 9671967] 
[195] 
von der Ahe, D.; Huehnchen, P.; Balkaya, M.; Peruzzaro, S.; Endres, M.; Boehmerle, W. Suramin-Induced Neurotoxicity: Preclinical Models and Neuroprotective Strategies. Molecules,  2018, 23(2), E346.
[http://dx.doi.org/10.3390/molecules23020346] [PMID: 29414872] 
[196] 
Martin, K.; Bentaberry, F.; Dumoulin, C.; Miremont-Salamé, G.; Haramburu, F.; Dehais, J.; Schaeverbeke, T. Peripheral neuropathy associated with leflunomide: is there a risk patient profile? Pharmacoepidemiol. Drug Saf.,  2007, 16(1), 74-78.
[http://dx.doi.org/10.1002/pds.1282] [PMID: 16845649] 
[197] 
Kho, L.K.; Kermode, A.G. Leflunomide-induced peripheral neuropathy. J. Clin. Neurosci.,  2007, 14(2), 179-181.
[http://dx.doi.org/10.1016/j.jocn.2005.08.021] [PMID: 17107800] 
[198] 
Richards, B.L.; Spies, J.; McGill, N.; Richards, G.W.; Vaile, J.; Bleasel, J.F.; Youssef, P.P. Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. Intern. Med. J.,  2007, 37(2), 101-107.
[http://dx.doi.org/10.1111/j.1445-5994.2007.01266.x] [PMID: 17229252] 
[199] 
Breedveld, F.C.; Dayer, J.M. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis.,  2000, 59(11), 841-849.
[http://dx.doi.org/10.1136/ard.59.11.841] [PMID: 11053058] 
[200] 
Weaver, A.; Caldwell, J.; Olsen, N.; Cohen, S.; Strand, V. Treatment of active rheumatoid arthritis with leflunomide compared to placebo or methotrexate. Arthritis Rheum.,  1998, 41(9)
[201] 
Mladenovic, V.; Domljan, Z.; Rozman, B.; Jajic, I.; Mihajlovic, D.; Dordevic, J. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis & Rheumatism. Official Journal of the American College of Rheumatology.,  1995, 38(11), 1595-1603.
[PMID: 7488280] 
[202] 
Weber, W; Harnisch, L Leflunomide in rheumatoid arthritis: population pharmacokinetic analysis of phase III studies. Rheumatol Eur1998, 1998.
[203] 
Cohen, S.; Cannon, G.W.; Schiff, M.; Weaver, A.; Fox, R.; Olsen, N.; Furst, D.; Sharp, J.; Moreland, L.; Caldwell, J.; Kaine, J.; Strand, V. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum.,  2001, 44(9), 1984-1992.
[http://dx.doi.org/10.1002/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B] [PMID: 11592358] 
[204] 
Rozman, B. Clinical pharmacokinetics of leflunomide. Clin. Pharmacokinet.,  2002, 41(6), 421-430.
[http://dx.doi.org/10.2165/00003088-200241060-00003] [PMID: 12074690] 
[205] 
Bonnel, R.A.; Graham, D.J. Peripheral neuropathy in patients treated with leflunomide. Clin. Pharmacol. Ther.,  2004, 75(6), 580-585.
[http://dx.doi.org/10.1016/j.clpt.2004.01.016] [PMID: 15179412] 
[206] 
Martin, K.; Bentaberry, F.; Dumoulin, C.; Longy-Boursier, M.; Lifermann, F.; Haramburu, F.; Dehais, J.; Schaeverbeke, T.; Bégaud, B.; Moore, N. Neuropathy associated with leflunomide: a case series. Ann. Rheum. Dis.,  2005, 64(4), 649-650.
[http://dx.doi.org/10.1136/ard.2004.027193] [PMID: 15769926] 
[207] 
Carulli, M.T.; Davies, U.M. Peripheral neuropathy: an unwanted effect of leflunomide? Rheumatology (Oxford),  2002, 41(8), 952-953.
[http://dx.doi.org/10.1093/rheumatology/41.8.952] [PMID: 12154221] 
[208] 
Fleming, A.; Dodman, S.; Crown, J.M.; Corbett, M. Extra-articular features in early rheumatoid disease. BMJ,  1976, 1(6020), 1241-1243.
[http://dx.doi.org/10.1136/bmj.1.6020.1241] [PMID: 1083759] 
[209] 
Weller, R.O.; Bruckner, F.E.; Chamberlain, M.A. Rheumatoid neuropathy: a histological and electrophysiological study. J. Neurol. Neurosurg. Psychiatry,  1970, 33(5), 592-604.
[http://dx.doi.org/10.1136/jnnp.33.5.592] [PMID: 4320255] 
[210] 
Schlumpf, U.; Meyer, M.; Ulrich, J.; Friede, R.L. Neurologic complications induced by gold treatment. Arthritis Rheum.,  1983, 26(7), 825-831.
[http://dx.doi.org/10.1002/art.1780260702] [PMID: 6409125] 
[211] 
Lescher, F.G. Nervous complications following treatment by gold salts. BMJ,  1936, 2(3964), 1303-1305.
[http://dx.doi.org/10.1136/bmj.2.3964.1303] [PMID: 20780372] 
[212] 
Sundelin, FF Die Goldbehandlung der chronischen Arthritis unter besonderer Berücksichtigung der Komplikationen: aus" Nynäs Kuranstalt", Krankenhaus d. schwed. kgl. Pensionsdirektion f. Nerven-u. Rheumakranke, u. aus d. Staatl. Inst. f. menschl. Erblichkeitsforschg u. Rassenbiologie zu Uppsala: Acta Medica Skandinavica 1941.
[213] 
Chang, R.J.; Persellin, R.H. Gold thiomalate-induced weight gain in guinea pigs. Proc. Soc. Exp. Biol. Med.,  1968, 129(2), 568-571.
[http://dx.doi.org/10.3181/00379727-129-33372] [PMID: 5696784] 
[214] 
Endtz, L.J. Complications nerveuses du traitement aurique; aperçu des symptomes neurologiques et psychiatriques; résultats du traitement par le B.A.L. Rev. Neurol. (Paris),  1958, 99(3), 395-410.
[PMID: 13624417] 
[215] 
Meyer, M.; Haecki, M.; Ziegler, W.; Forster, W.; Schiller, H. Autonomic dysfunction and myokymia in gold neuropathy. Peripheral Neuropathies; Elsevier, 1978, pp. 475-480.
[216] 
Walsh, J.C. Gold neuropathy. Neurology,  1970, 20(5), 455-458.
[http://dx.doi.org/10.1212/WNL.20.5.455] [PMID: 4314824] 
[217] 
Tegnér, R.; Tomé, F.M.; Godeau, P.; Lhermitte, F.; Fardeau, M. Morphological study of peripheral nerve changes induced by chloroquine treatment. Acta Neuropathol.,  1988, 75(3), 253-260.
[http://dx.doi.org/10.1007/BF00690533] [PMID: 2831692] 
[218] 
Sghirlanzoni, A.; Mantegazza, R.; Mora, M.; Pareyson, D.; Cornelio, F. Chloroquine myopathy and myasthenia-like syndrome. Muscle Nerve,  1988, 11(2), 114-119.
[http://dx.doi.org/10.1002/mus.880110205] [PMID: 3343986] 
[219] 
Garcin, R.; Rondot, P.; Fardeau, M. Sur les accidents neuromusculaires et en particulier sur une “myopathie vacuolaire” observés au cours d’un traitement prolongé par la chloroquine. Rev. Neurol. (Paris),  1964, 111, 177-195.
[220] 
Bonard, E.C. Neuropathy caused by chloroquine. Schweiz. Med. Wochenschr.,  1966, 96(34), 1103-1105.
[PMID: 5985860] 
[221] 
Lhermitte, F.; Marteau, R.; Chedru, F.; Mallecourt, J.; Estrade, G.; Godet-Guillain, J.; Chevallay, M. Chloroquine neuromyopathy. One case in prophylactic maleriatherapy (author’s transl). Nouv. Presse Med.,  1977, 6(35), 3205-3207.
[PMID: 200890] 
[222] 
Victor, M. Myopathies due to drugs, toxins, and nutritional deficiency. Myology.,  1994, 2, 1697-1725.
[223] 
Chloroquine neuromyopathy. Whisnant, J.; Espinosa, R.; Kierland, R.; Lambert, E., Eds.; Proceedings of the staff meetings Mayo Clinic, 1963.
[224] 
Mastaglia, F.L.; Papadimitriou, J.M.; Dawkins, R.L.; Beveridge, B. Vacuolar myopathy associated with chloroquine, lupus erythematosus and thymoma. Report of a case with unusual mitochondrial changes and lipid accumulation in muscle. J. Neurol. Sci.,  1977, 34(3), 315-328.
[http://dx.doi.org/10.1016/0022-510X(77)90149-6] [PMID: 591993] 
[225] 
Neville, H.E.; Maunder-Sewry, C.A.; McDougall, J.; Sewell, J.R.; Dubowitz, V. Chloroquine-induced cytosomes with curvilinear profiles in muscle. Muscle Nerve,  1979, 2(5), 376-381.
[http://dx.doi.org/10.1002/mus.880020509] [PMID: 492214] 
[226] 
Gérard, J-M.; Stoupel, N.; Collier, A.; Flament-Durand, J. Morphologic study of a neuromyopathy caused by prolonged chloroquine treatment. Eur. Neurol.,  1973, 9(6), 363-379.
[http://dx.doi.org/10.1159/000114244] [PMID: 4712543] 
[227] 
Léger, J.M.; Puifoulloux, H.; Dancea, S.; Hauw, J.J.; Bouche, P.; Rougemont, D.; Laplane, D. Chloroquine neuromyopathies: 4 cases during antimalarial prevention. Rev. Neurol. (Paris),  1986, 142(10), 746-752.
[PMID: 3029852] 
[228] 
Bregman, C.L.; Buroker, R.A.; Hirth, R.S.; Crosswell, A.R.; Durham, S.K. Etoposide- and BMY-40481-induced sensory neuropathy in mice. Toxicol. Pathol.,  1994, 22(5), 528-535.
[http://dx.doi.org/10.1177/019262339402200508] [PMID: 7899782] 
[229] 
Grisold, W; Cavaletti, G; Windebank, AJ Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-oncology,  2012, 14(suppl_4), iv45-iv54.
[http://dx.doi.org/10.1093/neuonc/nos203] 
[230] 
Semiglazov, VF; Semiglazov, VV; Dashyan, GA; Ziltsova, EK; Ivanov, VG; Bozhok, AA Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor‐positive breast cancer. cancer,  2007, 110(2), 244-254.
[231] 
Nishihori, T.; Choi, J.; DiGiovanna, M.P.; Thomson, J.G.; Kohler, P.C.; McGurn, J.; Chung, G.G. Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer. Clin. Breast Cancer,  2008, 8(4), 362-365.
[http://dx.doi.org/10.3816/CBC.2008.n.043] [PMID: 18757265] 
[232] 
Shoults, K. Case report: neurological complications of nitrous oxide abuse. BCMJ,  2016, 58, 192-194.
[233] 
Safari, A.; Emadi, F.; Jamali, E.; Borhani-Haghighi, A. Clinical and MRI manifestations of nitrous oxide induced vitamin B12 deficiency: A case report. Iran. J. Neurol.,  2013, 12(3), 111-113.
[PMID: 24250916] 
[234] 
Moddel, G.; Bilbao, J.M.; Payne, D.; Ashby, P. Disulfiram neuropathy. Arch. Neurol.,  1978, 35(10), 658-660.
[http://dx.doi.org/10.1001/archneur.1978.00500340034006] [PMID: 211996] 
[235] 
Tran, A.T.; Rison, R.A.; Beydoun, S.R. Disulfiram neuropathy: two case reports. J. Med. Case Reports,  2016, 10(1), 72.
[http://dx.doi.org/10.1186/s13256-016-0865-z] [PMID: 27029711] 
[236] 
Kuncl, R.W.; Duncan, G.; Watson, D.; Alderson, K.; Rogawski, M.A.; Peper, M. Colchicine myopathy and neuropathy. N. Engl. J. Med.,  1987, 316(25), 1562-1568.
[http://dx.doi.org/10.1056/NEJM198706183162502] [PMID: 3035372] 
[237] 
Shrestha, S.; Chaudhary, S.; Giri, H.; Marahatta, S. Dapsone-induced optic atrophy: a rare case report. Lepr. Rev.,  2020, 91, 291-294.
[http://dx.doi.org/10.47276/lr.91.3.291] 
[238] 
Choi, S.S.; Chan, K.F.; Ng, H.K.; Mak, W.P. Colchicine-induced myopathy and neuropathy. Hong Kong Med. J.,  1999, 5(2), 204-207.
[PMID: 11821595] 
[239] 
Wong, Sh.; Silva, F.; Acheson, J.; Plant, G. An old friend revisited: chloramphenicol optic neuropathy. JRSM Short Rep.,  2013, 4(3), 20.
[http://dx.doi.org/10.1177/2042533313476692] [PMID: 23560219] 
[240] 
Chalioulias, K.; Mayer, E.; Darvay, A.; Antcliff, R. Anterior ischaemic optic neuropathy associated with Dapsone. Eye (Lond.),  2006, 20(8), 943-945.
[http://dx.doi.org/10.1038/sj.eye.6702050] [PMID: 16215545] 
[241] 
McCarty, M. How clinically relevant is dapsone-related peripheral neuropathy?: an overview of available data with emphasis on clinical recognition. J. Clin. Aesthet. Dermatol.,  2010, 3(3), 19-21.
[PMID: 20725539] 
[242] 
Fang, J.T.; Chen, Y.C.; Chang, M.Y. Ethambutol-induced optic neuritis in patients with end stage renal disease on hemodialysis: two case reports and literature review. Ren. Fail.,  2004, 26(2), 189-193.
[http://dx.doi.org/10.1081/JDI-120038521] [PMID: 15287205] 
[243] 
Tugwell, P.; James, S.L. Peripheral neuropathy with ethambutol. Postgrad. Med. J.,  1972, 48(565), 667-670.
[http://dx.doi.org/10.1136/pgmj.48.565.667] [PMID: 4346665] 
[244] 
Si, M.; Li, H.; Chen, Y.; Peng, H. Ethambutol and isoniazid induced severe neurotoxicity in a patient undergoing continuous ambulatory peritoneal dialysis. BMJ Case Rep.,  2018, 2018, bcr-2017-bcr-223187.
[http://dx.doi.org/10.1136/bcr-2017-223187] [PMID: 29776936] 
[245] 
Cohen, J.S. Peripheral neuropathy associated with fluoroquinolones. Ann. Pharmacother.,  2001, 35(12), 1540-1547.
[http://dx.doi.org/10.1345/aph.1Z429] [PMID: 11793615] 
[246] 
Popescu, C. Severe acute axonal neuropathy induced by ciprofloxacin: a case report. Case Rep. Neurol.,  2018, 10(2), 124-129.
[http://dx.doi.org/10.1159/000489303] [PMID: 29928218] 
[247] 
Tan, I.L.; Polydefkis, M.J.; Ebenezer, G.J.; Hauer, P.; McArthur, J.C. Peripheral nerve toxic effects of nitrofurantoin. Arch. Neurol.,  2012, 69(2), 265-268.
[http://dx.doi.org/10.1001/archneurol.2011.1120] [PMID: 22332195] 
[248] 
Toole, J.F.; Parrish, M.L. Nitrofurantoin polyneuropathy. Neurology,  1973, 23(5), 554-559.
[http://dx.doi.org/10.1212/WNL.23.5.554] [PMID: 4349239] 
[249] 
Cação, G.; Fontes, S.; Salgado, M.; Rodrigues, T.; Damásio, J. Metronidazole-induced central and peripheral nervous system toxicity. Neurol. Sci.,  2015, 36(9), 1737-1739.
[http://dx.doi.org/10.1007/s10072-015-2260-8] [PMID: 25990105] 
[250] 
Sharma, P.; Sharma, R. Toxic optic neuropathy. Indian J. Ophthalmol.,  2011, 59(2), 137-141.
[http://dx.doi.org/10.4103/0301-4738.77035] [PMID: 21350283] 
[251] 
Zaworski, J.; Delannoy, P-Y.; Boussekey, N.; Thellier, D.; Georges, H.; Leroy, O. Lithium: one drug, five complications. J. Intensive Care,  2017, 5(1), 70.
[http://dx.doi.org/10.1186/s40560-017-0257-5] [PMID: 29276608] 
[252] 
Shorvon, S.D.; Reynolds, E.H. Anticonvulsant peripheral neuropathy: a clinical and electrophysiological study of patients on single drug treatment with phenytoin, carbamazepine or barbiturates. J. Neurol. Neurosurg. Psychiatry,  1982, 45(7), 620-626.
[http://dx.doi.org/10.1136/jnnp.45.7.620] [PMID: 6288881] 
[253] 
Kirkendall, W.M.; Page, E.B. Polyneuritis occurring during hydralazine therapy; report of two cases and discussion of adverse reactions to hydralazine. J. Am. Med. Assoc.,  1958, 167(4), 427-432.
[http://dx.doi.org/10.1001/jama.1958.02990210013003] [PMID: 13538717] 
[254] 
Tsujimoto, G.; Horai, Y.; Ishizaki, T.; Itoh, K. Hydralazine-induced peripheral neuropathy seen in a Japanese slow acetylator patient. Br. J. Clin. Pharmacol.,  1981, 11(6), 622-625.
[http://dx.doi.org/10.1111/j.1365-2125.1981.tb01181.x] [PMID: 6268134] 
[255] 
Bhalla, S.; Singh, N.; Jaggi, A.S. Statins: do they aggravate or ameliorate neuropathic pain? J. Pain,  2014, 15(11), 1069-1080.
[http://dx.doi.org/10.1016/j.jpain.2014.06.012] [PMID: 25086324] 
[256] 
Emad, M.; Arjmand, H.; Farpour, H.R.; Kardeh, B. Lipid-lowering drugs (statins) and peripheral neuropathy. Electron. Physician,  2018, 10(3), 6527-6533.
[http://dx.doi.org/10.19082/6527] [PMID: 29765578] 
[257] 
Erdem, S.; Freimer, M.L.; O’Dorisio, T.; Mendell, J.R. Procainamide-induced chronic inflammatory demyelinating polyradiculoneuropathy. Neurology,  1998, 50(3), 824-825.
[http://dx.doi.org/10.1212/WNL.50.3.824] [PMID: 9521292] 
[258] 
Hooijmans, C.R.; Draper, D.; Ergün, M.; Scheffer, G.J. The effect of analgesics on stimulus evoked pain-like behaviour in animal models for chemotherapy induced peripheral neuropathy- a meta-analysis. Sci. Rep.,  2019, 9(1), 17549.
[http://dx.doi.org/10.1038/s41598-019-54152-8] [PMID: 31772391] 
[259] 
Matthews, E.A.; Dickenson, A.H. A combination of gabapentin and morphine mediates enhanced inhibitory effects on dorsal horn neuronal responses in a rat model of neuropathy. Anesthesiology,  2002, 96(3), 633-640.
[http://dx.doi.org/10.1097/00000542-200203000-00020] [PMID: 11873039] 
[260] 
Moulin, D.E.; Palma, D.; Watling, C.; Schulz, V. Methadone in the management of intractable neuropathic noncancer pain. Can. J. Neurol. Sci.,  2005, 32(3), 340-343.
[http://dx.doi.org/10.1017/S0317167100004236] [PMID: 16225176] 
[261] 
Mannino, R.; Coyne, P.; Swainey, C.; Hansen, L.A.; Lyckholm, L. Methadone for cancer-related neuropathic pain: a review of the literature. J. Opioid. Manag.,  2006, 2(5), 269-276.
[http://dx.doi.org/10.5055/jom.2006.0040] [PMID: 17319258] 
[262] 
Rahn, E.J.; Hohmann, A.G. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics,  2009, 6(4), 713-737.
[http://dx.doi.org/10.1016/j.nurt.2009.08.002] [PMID: 19789075] 
[263] 
Fornasari, D. Pharmacotherapy for neuropathic pain: a review. Pain Ther.,  2017, 6(1)(Suppl. 1), 25-33.
[http://dx.doi.org/10.1007/s40122-017-0091-4] [PMID: 29178034] 
[264] 
Sindrup, S.H.; Otto, M.; Finnerup, N.B.; Jensen, T.S. Antidepressants in the treatment of neuropathic pain. Basic Clin. Pharmacol. Toxicol.,  2005, 96(6), 399-409.
[http://dx.doi.org/10.1111/j.1742-7843.2005.pto_96696601.x] [PMID: 15910402] 
[265] 
Dharmshaktu, P.; Tayal, V.; Kalra, B.S. Efficacy of antidepressants as analgesics: a review. J. Clin. Pharmacol.,  2012, 52(1), 6-17.
[http://dx.doi.org/10.1177/0091270010394852] [PMID: 21415285] 
[266] 
Lee, Y-C.; Chen, P-P. A review of SSRIs and SNRIs in neuropathic pain. Expert Opin. Pharmacother.,  2010, 11(17), 2813-2825.
[http://dx.doi.org/10.1517/14656566.2010.507192] [PMID: 20642317] 
[267] 
Taylor, C.P.; Angelotti, T.; Fauman, E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res.,  2007, 73(2), 137-150.
[http://dx.doi.org/10.1016/j.eplepsyres.2006.09.008] [PMID: 17126531] 
[268] 
Hincker, A.; Frey, K.; Rao, L.; Wagner-Johnston, N.; Ben Abdallah, A.; Tan, B.; Amin, M.; Wildes, T.; Shah, R.; Karlsson, P.; Bakos, K.; Kosicka, K.; Kagan, L.; Haroutounian, S. Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled, crossover study. Pain,  2019, 160(8), 1835-1846.
[http://dx.doi.org/10.1097/j.pain.0000000000001577] [PMID: 31335651] 
[269] 
Visovsky, C.; Collins, M.; Abbott, L.; Aschenbrenner, J.; Hart, C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin. J. Oncol. Nurs.,  2007, 11(6), 901-913.
[http://dx.doi.org/10.1188/07.CJON.901-913] [PMID: 18063548] 
[270] 
Limb Hypothermia for the Prevention of Chemotherapy-Induced Peripheral Neuropathy-Modality for Optimal Cooling. Bandla, A.; Santhanakrishnan, P.; Magarajah, G.; Vaidya, G.A.; Subramanian, A.; Wei, H., Eds.; 42nd Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC), IEEE2020.
[271] 
van den Hurk, C.J.; Peerbooms, M.; van de Poll-Franse, L.V.; Nortier, J.W.; Coebergh, J.W.W.; Breed, W.P. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta Oncol.,  2012, 51(4), 497-504.
[http://dx.doi.org/10.3109/0284186X.2012.658966] [PMID: 22304489] 
[272] 
Kennet, J.; Hardaker, N.; Hobbs, S.; Selfe, J. Cooling efficiency of 4 common cryotherapeutic agents. J. Athl. Train.,  2007, 42(3), 343-348.
[PMID: 18059988] 
[273] 
Kanlayanaphotporn, R.; Janwantanakul, P. Comparison of skin surface temperature during the application of various cryotherapy modalities. Arch. Phys. Med. Rehabil.,  2005, 86(7), 1411-1415.
[http://dx.doi.org/10.1016/j.apmr.2004.11.034] [PMID: 16003673] 
[274] 
Hanai, A.; Ishiguro, H.; Sozu, T.; Tsuda, M.; Yano, I.; Nakagawa, T.; Imai, S.; Hamabe, Y.; Toi, M.; Arai, H.; Tsuboyama, T. Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: prospective self-controlled trial. JNCI. J. Natl. Cancer Inst.,  2018, 110(2), 141-148.
[http://dx.doi.org/10.1093/jnci/djx178] [PMID: 29924336] 
[275] 
Eckhoff, L.; Knoop, A.S.; Jensen, M-B.; Ejlertsen, B.; Ewertz, M. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res. Treat.,  2013, 142(1), 109-118.
[http://dx.doi.org/10.1007/s10549-013-2728-2] [PMID: 24132874] 
[276] 
Scotté, F.; Banu, E.; Medioni, J.; Levy, E.; Ebenezer, C.; Marsan, S.; Banu, A.; Tourani, J.M.; Andrieu, J.M.; Oudard, S. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer,  2008, 112(7), 1625-1631.
[http://dx.doi.org/10.1002/cncr.23333] [PMID: 18286527] 
[277] 
Kanbayashi, Y.; Sakaguchi, K.; Ishikawa, T.; Ouchi, Y.; Nakatsukasa, K.; Tabuchi, Y.; Kanehisa, F.; Hiramatsu, M.; Takagi, R.; Yokota, I.; Katoh, N.; Taguchi, T. Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial. Breast,  2020, 49, 219-224.
[http://dx.doi.org/10.1016/j.breast.2019.12.011] [PMID: 31901783] 
[278] 
Barber, F.A.; McGuire, D.A.; Click, S. Continuous-flow cold therapy for outpatient anterior cruciate ligament reconstruction. Arthroscopy,  1998, 14(2), 130-135.
[http://dx.doi.org/10.1016/S0749-8063(98)70030-1] [PMID: 9531122] 
[279] 
Murgier, J.; Cassard, X. Cryotherapy with dynamic intermittent compression for analgesia after anterior cruciate ligament reconstruction. Preliminary study. Orthop. Traumatol. Surg. Res.,  2014, 100(3), 309-312.
[http://dx.doi.org/10.1016/j.otsr.2013.12.019] [PMID: 24679367] 
[280] 
Sundar, R.; Bandla, A.; Tan, S.S.H.; Liao, L-D.; Kumarakulasinghe, N.B.; Jeyasekharan, A.D.; Ow, S.G.; Ho, J.; Tan, D.S.; Lim, J.S.; Vijayan, J.; Therimadasamy, A.K.; Hairom, Z.; Ang, E.; Ang, S.; Thakor, N.V.; Lee, S.C.; Wilder-Smith, E.P. Limb hypothermia for preventing paclitaxel-induced peripheral neuropathy in breast cancer patients: a pilot study. Front. Oncol.,  2017, 6, 274.
[http://dx.doi.org/10.3389/fonc.2016.00274] [PMID: 28119855] 
[281] 
Oneda, E.; Meriggi, F.; Zanotti, L.; Zaina, E.; Bighè, S.; Andreis, F.; Rueda, S.; Zaniboni, A. Innovative Approach for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Pilot Study With the Hilotherm Device, the Poliambulanza Hospital Experience. Integr. Cancer Ther.,  2020, 19, 1534735420943287.
[http://dx.doi.org/10.1177/1534735420943287] [PMID: 32856475] 
[282] 
Argyriou, A.A.; Bruna, J.; Park, S.B.; Cavaletti, G. Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms. Expert Rev. Neurother.,  2020, 20(10), 1005-1016.
[http://dx.doi.org/10.1080/14737175.2020.1796639] [PMID: 32667212] 
[283] 
Chen, M. Interactions between multi-kinase inhibitors and solute carrier transporters; The Ohio State University, 2020. 
[284] 
Karlsson, J.O.G.; Ignarro, L.J.; Lundström, I.; Jynge, P.; Almén, T. Calmangafodipir [Ca4Mn(DPDP)5], mangafodipir (MnDPDP) and MnPLED with special reference to their SOD mimetic and therapeutic properties. Drug Discov. Today,  2015, 20(4), 411-421.
[http://dx.doi.org/10.1016/j.drudis.2014.11.008] [PMID: 25463039] 
[285] 
Morrison, E.E.; Oatey, K.; Gallagher, B.; Grahamslaw, J.; O’Brien, R.; Black, P.; Oosthuyzen, W.; Lee, R.J.; Weir, C.J.; Henriksen, D.; Dear, J.W. Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial). EBioMedicine,  2019, 46, 423-430.
[http://dx.doi.org/10.1016/j.ebiom.2019.07.013] [PMID: 31311721] 
[286] 
Shinbo, T.; Kokubo, K.; Sato, Y.; Hagiri, S.; Hataishi, R.; Hirose, M.; Kobayashi, H. Breathing nitric oxide plus hydrogen gas reduces ischemia-reperfusion injury and nitrotyrosine production in murine heart. Am. J. Physiol. Heart Circ. Physiol.,  2013, 305(4), H542-H550.
[http://dx.doi.org/10.1152/ajpheart.00844.2012] [PMID: 23771690] 
[287] 
Hu, S.; Huang, K.M.; Adams, E.J.; Loprinzi, C.L.; Lustberg, M.B. Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin. Cancer Res.,  2019, 25(21), 6295-6301.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-2152] [PMID: 31123053] 
[288] 
Cavalli, E.; Mammana, S.; Nicoletti, F.; Bramanti, P.; Mazzon, E. The neuropathic pain: An overview of the current treatment and future therapeutic approaches. Int. J. Immunopathol. Pharmacol.,  2019, 33, 2058738419838383.
[http://dx.doi.org/10.1177/2058738419838383] [PMID: 30900486] 
[289] 
Kyte, S.L.; Toma, W.; Bagdas, D.; Meade, J.A.; Schurman, L.D.; Lichtman, A.H.; Chen, Z.J.; Del Fabbro, E.; Fang, X.; Bigbee, J.W.; Damaj, M.I.; Gewirtz, D.A. Nicotine prevents and reverses paclitaxel-induced mechanical allodynia in a mouse model of CIPN. J. Pharmacol. Exp. Ther.,  2018, 364(1), 110-119.
[http://dx.doi.org/10.1124/jpet.117.243972] [PMID: 29042416] 
Rights & Permissions Print Cite
Article Metrics
90
1
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1568009621666210720142542	Print ISSN 1568-0096
Publisher Name Bentham Science Publisher	Online ISSN 1873-5576
Current Cancer Drug Targets

Drug-Induced Peripheral Neuropathy: Diagnosis and Management

Abstract

Innovative Cancer Drug Targets: A New Horizon in Oncology

Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment

The Impact of Cancer Neuroscience on Novel Brain Cancer Treatment

Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics

Current Cancer Drug Targets

Drug-Induced Peripheral Neuropathy: Diagnosis and Management

Abstract

Call for Papers in Thematic Issues

Innovative Cancer Drug Targets: A New Horizon in Oncology

Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment

The Impact of Cancer Neuroscience on Novel Brain Cancer Treatment

Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics

Related Journals

Related Books

Related Articles
